GlassScriptPhysician profile
Holly J Kramer
NPI 1003893975
$89,385.44
in general payments reported to CMS, 2019-2025
14 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $5,829 · 2021: $23K · 2022: $37K · 2023: $840 · 2024: $1,368 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,280 · Travel and Lodging: $1,641 · Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,887.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,280.00 |
| Travel and Lodging | $1,641.17 |
| Food and Beverage | $477.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $77,540.14 | 2020-2025 | |
| Vifor Pharma, INC. | $4,391.85 | 2022 | |
| Alexion Pharmaceuticals, INC. | $2,600.00 | 2019-2025 | |
| Eli Lilly and Company | $2,280.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,139.50 | 2021 | |
| Roche Products Limited | $190.26 | 2023 | Gazyva |
| Medtronic, INC. | $93.23 | 2023 | Endurant Iis |
| Outset Medical INC | $38.99 | 2019 | |
| Tolmar, INC. | $34.78 | 2023 | |
| Ascendis Pharma Endocrinology INC | $28.60 | 2023 | |
| Novartis Pharmaceuticals Corporation | $21.17 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.94 | 2019 | |
| Amgen INC. | $12.98 | 2023 | Repatha |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.